Core Viewpoint - Eli Lilly is experiencing significant growth driven by its diabetes drug Mounjaro and weight loss drug Zepbound, but there are concerns about sustaining this growth and the company's high valuation [2][8][10]. Group 1: Growth Drivers - Eli Lilly's operating income has increased by 90.7% over the last three years, reaching $15.1 billion, largely due to the success of Mounjaro and Zepbound [2]. - The company is investing heavily in manufacturing, with a recent $3 billion expansion in Wisconsin, bringing total investment in the site to $4 billion, indicating expectations for increased demand [3][4]. - Clinical trials suggest Zepbound is more effective for weight loss than its competitor Wegovy, with patients losing 47% more weight after 72 weeks, which could enhance market share [6]. Group 2: Cautionary Factors - There are signs that the rapid growth may be slowing, as drug wholesalers purchased fewer doses of Mounjaro and Zepbound in Q3 compared to previous quarters [8]. - Management indicated that wholesalers had previously stocked up on GLP-1 drugs, leading to a temporary inventory surplus, which may affect future sales growth [9]. - Eli Lilly's trailing P/E ratio is 86, indicating a high valuation that may lead to volatility if earnings do not meet investor expectations [10][11].

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs and fought for market share.In recent years, these two healthcare leaders have also been butting heads in the GLP-1 weight loss space. Eli Lilly's Zepbound and Novo Nordisk's Wegovy are the two most prominent brands in this area, which is projected to grow by leaps and bounds in the coming years. Which of these co ...

With drugs like Novo Nordisk's Wegovy becoming household names over the last couple of years, it's no surprise that there are quite a few opportunities to invest in the burgeoning market for weight-loss medicines.There are a pair of businesses that are particularly appealing on the basis of their proven or potential ability to compete in that market. Both of these companies have outperformed the market for at least the last 12 months, and there's ample reason to believe that the outperformance could continu ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the positive opinion  VIVID-1 was the first pivotal Crohn's disease trial to show benefits in hard-to-treat symptom of bowel urgency using a patient-centric scale Omvoh will be the first treatment for Crohn's disease with results demonstrating improvements of histologic measures of inflammation included in its label, if approved by the European CommissionLilly has als ...

Eli Lilly (LLY) announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease progression or death in certain patients with advanced breast cancer (ABC).The EMBER-3 study enrolled patients with estrogen receptor (ER)-positive, HER2-negative ABC whose disease progressed during or following an aromatase inhibitor (AI) therapy, with or without a CDK 4/6 inhibitor. These patients were then ...

Eli Lilly (LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world.Although it may seem like it has hit a peak given the stock's slowdown in recent weeks, there could be a huge catalyst upcoming for the business next year. It's one that investors should keep a close eye on because it could send the stock to record highs in 2025.Data from ...

Clinical Trial Results - Imlunestrant as monotherapy significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations [1] - Imlunestrant in combination with Verzenio reduced the risk of progression or death by 43% compared to imlunestrant alone, regardless of ESR1 mutation status [1] - Median progression-free survival (PFS) was 5.5 months with imlunestrant versus 3.8 months with standard of care ET in patients with ESR1 mutations [4] - Median PFS for imlunestrant-abemaciclib combination was 9.4 months versus 5.5 months for imlunestrant alone in all patients [6] - Overall response rate (ORR) was 27% for imlunestrant-abemaciclib versus 12% for imlunestrant alone [7] Study Design and Patient Population - EMBER-3 is a Phase 3, randomized, open-label study of imlunestrant, investigator's choice of endocrine therapy, and imlunestrant in combination with abemaciclib [11] - The trial enrolled 874 adult patients with ER+, HER2- locally advanced or metastatic breast cancer [11] - 32% of patients enrolled as first-line treatment for advanced breast cancer (ABC), and 64% as second-line treatment following progression on initial therapy [11] - Randomization was stratified by prior CDK4/6 inhibitor use, presence of visceral metastases, and geographic region [3] Safety and Tolerability - Safety profile of imlunestrant-abemaciclib was consistent with known safety profile of fulvestrant in combination with abemaciclib [8] - Most common adverse events included diarrhea (86%), nausea (49%), neutropenia (48%), and anemia (44%) [8] - Discontinuation rate due to adverse events was low at 6.3% [8] Market and Industry Context - Imlunestrant is an orally administered, brain penetrant, pure ER antagonist that delivers continuous ER target inhibition [9] - Current standard treatment for ER+ breast cancer after progression on initial endocrine therapy is fulvestrant, which is administered via intramuscular injection [9] - 72% of patients receiving fulvestrant reported injection site pain, swelling, or redness, highlighting the need for oral alternatives [9] - Imlunestrant is also being investigated in the adjuvant setting for ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence [10] Breast Cancer Epidemiology - Breast cancer is the second most commonly diagnosed cancer worldwide, with an estimated 2.3 million new cases in 2022 [13] - In the US, it is estimated that there will be more than 310,000 new cases of breast cancer diagnosed in 2024 [13] - Approximately 30% of high-risk early-stage breast cancer cases in the US will become metastatic [12] - Five-year relative survival rates are 99% for localized disease, 86% for regional/locally advanced disease, and 30% for metastatic/advanced disease [12]

Direct-to-consumer health-care startup Ro on Wednesday said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly, which aims to streamline access to the popular treatment. Ro said it will offer a "complete end-to-end" experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug delivered to their homes. That is made possible through a fir ...

Investment Rating - Buy rating with a target price of $981.8, implying an 18.8% upside from the current price of $827 [2][3] Core Thesis - Tirzepatide (Mounjaro and Zepbound) is expected to continue driving strong revenue growth for the company [2] - Q3 2024 revenue increased 20% YoY to $11.44 billion, with 42% growth excluding Zyprexa divestiture impact [2] - Global volume grew 36%, led by Mounjaro and Zepbound, while non-GLP-1 products also grew 17% [2] - Gross margin improved 0.6pp to 81.0% due to favorable product mix and pricing [2] - Q4 revenue growth is expected to reach 50%, with full-year revenue forecast at $45.4-46.0 billion and EPS of $12.1-12.6 [2] Segment Performance Metabolic - Q3 revenue grew 57% YoY to $7.41 billion, driven by 210% growth in Tirzepatide to $4.37 billion [2] - Mounjaro holds 34% TRx SOM in the US diabetes market, while Zepbound has 43% TRx SOM in obesity [2] - SURMOUNT-1 study showed Tirzepatide reduced risk of type 2 diabetes by 94% in pre-diabetic, obese or overweight adults [2] - Zepbound demonstrated superior weight loss (20.2%) vs Wegovy (13.7%) in head-to-head trials [2] Neuroscience - Q3 revenue declined 80% YoY to $350 million due to Zyprexa divestiture [2] - Kisunla (Alzheimer's drug) approved in US, Japan and UK, with ARIA-E incidence reduced from 24% to 14% through modified titration [2] Immunology - Q3 revenue grew 20% YoY to $1.19 billion [2] - Taltz (IL-17A) revenue increased 18% to $880 million due to price and demand growth [2] - Ebglyss (IL-13) approved for moderate-to-severe atopic dermatitis [2] Oncology - Q3 revenue grew 28% YoY to $2.23 billion [2] - Verzenio (CDK4/6) revenue increased 32% to $1.37 billion, driven by early breast cancer indication [2] Other - Q3 revenue declined 5% to $260 million [2] Financial Summary - 2024E revenue forecast at $45.8 billion, representing 34.1% YoY growth [4] - 2024E net profit expected to reach $11.0 billion, with 110.5% YoY growth [4] - 2024E EPS projected at $12.20, implying 110.3% YoY growth [4] - 2024E EBITDA margin forecast at 33.2%, up from 23.4% in 2023 [6] - 2024E net margin expected to improve to 24.1% from 15.4% in 2023 [6] - 2024E R&D expense ratio forecast at 24.5%, down from 27.3% in 2023 [6] - 2024E SG&A/Revenue ratio expected to decline to 18.5% from 21.7% in 2023 [6]